Press Release: CA Assembly Passes Bill to Rein in Outsized Costs in Dialysis, Drug Treatment Industries
The California State Assembly today passed legislation by a bipartisan vote to contain costs in the dialysis and drug treatment industries that currently result in higher health care costs for all consumers.
CAHP Statement: Response To Governor’s May Budget Revise Release
California Association of Health Plans (CAHP) President & CEO Charles Bacchi today issued the following statement in response to Gov. Gavin Newsom’s release of the May budget revise.
CAHP Fact Sheet: New Benefit Mandates Will Drive Up Health Care Costs for All
As providers of health care coverage for more than 26 million Californians, health plans are dedicated to ensuring that everyone has access to high quality, affordable health care.
CAHP Fact Sheet: California Health Plan Profit Margins: Lower Than You May Think.
The vast majority of health plan spending in California goes to pay for medical services like hospital and doctor visits, prescription drugs, lab tests, x-rays, and medical supplies.
CAHP Statement: CAHP Releases Research Review On Northwestern University Finding that Medicaid Managed Care Lowers Drug Costs
The California Association of Health Plans today has released a research review of a recent non-partisan nationwide study conducted by a team of Northwestern University professors which found that allowing managed care organizations (MCO’s) to administer the majority of Medicaid drug benefits, as we currently do in California, significantly reduces state spending on prescription drugs.
CAHP Statement: CAHP Hires New Director of Regulatory Affairs and State Programs Analyst
The California Association of Health Plans (CAHP) today announced that Christina Wu is the association’s new Director of Regulatory Affairs and Ellesse Flores has joined the staff as State Programs Analyst.
CAHP Statement: Bill Designed to Lower Prescription Drug Prices by Cracking Down on Pharma’s Pay-for-Delay Schemes Passes Assembly Health Committee
AB 824, a bill that would curb increasing drug prices in Californiaby allowing more generic drugs to enter thehealth caremarketplace, cleared the Assembly Health Committee this afternoon. The measure, introduced by Assembly Health Committee Chairman Jim Wood (D-Santa Rosa)inpartnership with Attorney General Xavier Becerra, would prohibit “pay-for-delay” agreements where a pharmaceutical company transfers anything of value to delay a competitor’s research, marketing, or sale of a competing version of its drug.
CAHP Statement: Assembly Health Committee Passes Bill to Stop Third Party Payer Scheme from Driving Up Health Care Costs for All
Legislation designed toincreaseconsumer protection by reining-in a profiteering scheme operated by the dialysis and drug rehabilitation industries passed the Assembly Health Committee on a bipartisan vote.
Infographic: How Prescription Drug Costs Impact California Health Plan Premiums
In 2017, California enacted into law SB 17, groundbreaking legislation that is helping to shine a light on pharmaceutical companies’ efforts to spike prescription drug prices.
Infographic: How SB17 Works and Key Dates for 2019
SB 17 will help bring pharmaceutical companies’ pricing tactics out of the dark and address the growing affordability crisis by requiring drug companies to give health plans and others notice of major price increases for the most expensive drugs. While some key details of the law have been implemented, there is still much more activity to come in 2019.
CAHP Applauds Covered California, DHCS Actions to Address COVID-19 Crisis
/in News, Press Releases /by Connie FloresCAHP Names New Vice President of State Medicaid Policy and Legislative Advocate
/in News, Press Releases /by Connie Flores